skip to Main Content

Same Meds, New Patents: What Do Activists Need to Know About Long-Acting Technologies

Archives:

On November 4, 2021, Treatment Action Group and the International Treatment Preparedness Coalition presented this webinar outlining the main findings of the upcoming report “Hepatitis C and Tuberculosis Long-Acting Medicines: Analysis on Patenting Trends.”

Long Acting Formulations (LAF) are being developed to deliver treatment in innovative ways, making treatment potentially easier to adhere to, less-stigmatizing and accessible. The LONGEVITY project, sponsored by Unitaid, is working on developing Hepatitis C and Tuberculosis treatments using LAF technology. The report analyzed the patent landscape of the four drugs under the LONGEVITY project and two Tuberculosis drugs that are being sponsored by other institutions, discussing the potential implications of intellectual property to the access of LAF of these drugs. The webinar will present what LAF are, how they can affect hepatitis C and tuberculosis treatment and the main intellectual property hurdles that can curtail the access to these formulations. We hope that by understanding more about LAF technologies and the state of intellectual property barriers analyzed in this study,  civil society, researchers, international organizations and patients can take active steps to ensure access to the final products.

A panel of treatment activists with the Make Medicines Affordable campaign shared different country perspectives on using intellectual property flexibilities in the long-acting technologies space.

The webinar recording is below, and you can download the presentation from the link in the right column.

Moderators:
Bryn Gay and Joelle Dountio Ofimboudem of Treatment Action Group
Othoman Mellouk of ITPC

Speaker:

photo of gabriela chavesGabriela Chaves has over 15 years of experience working on approaches to address barriers to access to medicines, including patent barriers.  For several years she worked for civil society organizations in Brazil advocating for solutions and campaigning on the problem of high prices of monopoly HIV medicines. As a researcher in public health, she has pioneered studies related the analysis and practical solutions on the effects on access to medicines and procurement policies of intellectual property rights and industrial policies in Brazil, including a patent landscape for 74 medicines financed by the Ministry of Health.

Panelists

photo of pedro villardiPedro Villardi is the coordinator of the Working Group of Intellectual Property (GTPI) of the Brazilian Network for the People’s Integration and project coordinator of the Brazilian Aids Interdisciplinary Association (ABIA). He also has a degree in International Studies at PUC-Rio, a master’s in Bioethics and Public Health, and has a Ph.D. in Social Sciences and Health at the Institute of Social Medicine of UERJ (IMS/UERJ). Villardi has worked and researched access to medicines, pharmaceutical patents, and global health for more than ten years. He has authored several papers, chapters, and books on the issue.

photo of mykyta trofymenkoMykyta Trofymenko is an Intellectual Property Counsel at the charitable organization 100% Life (Ukraine). Mr. Trofymenko holds a Master’s degree in law (2012), a degree in Intellectual Property (2016) and was a Scholar-in-Residence at the Program on Information Justice and Intellectual Property at the American University Washington College of Law (2017-2018). For more than 8 years he has been working on the issues related to intellectual property, patents, pharmaceuticals and public health.

photo of chalermsak kittitrakulChalermsak Kittitrakul started his career related to free trade agreements (FTAs), intellectual property (IP), and access to anti-retroviral medicines (ARVs). He worked with academics and civic groups to encourage the Thai government to implement the Government Use License to promote access to lifesaving drugs. Since 2013 he has worked with AIDS Access Foundation,
as Project Manager for Access to Medicines, and continues monitoring policies affecting access to medicines.

 

Back To Top